Briefly, PBMCs were incubated with saturating concentrations of CD14 microbeads at 4 °C for 15 min, washed and suspended in PBS containing SAHA HDAC manufacturer 2 mm ethylenediaminetetraacetic acid and 0.5% bovine serum albumin (BSA). The cell suspension was then applied
to the autoMACS separator using the positive selection programme. The CD14-positive cells were eluted from the magnetic column; a purity of >98% was routinely obtained as confirmed by flow cytometry. Previous studies using mRNA profiling as readout have demonstrated that isolation procedures do not result Omipalisib manufacturer in relevant activation of the isolated cells. Naïve PBMCs and naïve CD14+ monocytes were recuperated in culture for 24 h in DMEM supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin and 2 mm L-glutamine (DMEM+), with 10% heat-inactivated human male AB serum. Naïve PBMCs were cultured in 96-well plate (Nunc) at a concentration of 1 × 105 PBMCs per well according to standard procedures, whereas naïve CD14+ monocytes
were cultured in 24-well plate at a concentration of 1 × 106 cells per well. Both naïve PBMCs and naïve CD14+ monocytes were cultured in a cell/tissue incubator under 5% CO2 in air (pH7.4), at 37 °C and 95% humidity. After the 24 h of recuperation, medium was replaced with serum-free DMEM+ with additives according to the experimental conditions, and cells were cultured for an additional 24 h. Experimental conditions included stimulation with FVIIa [25 nm], TF [37 pm] + FVIIa
[25 nm], Bumetanide TF [37 pm] + FVIIa [25 nm] + FX [100 nm], FX [100 nm], FXa [10 nm] or Thrombin [300 nm]. These concentrations correspond with a FVIIa dose of 90 μg/kg body weight for FVIIa in case of treatment and known estimated physiological intravascular concentrations of TF [37 pm], FX [135 nm], FXa [13.5 nm] and thrombin [2–300 nm] [.] For reverse transcription–polymerase chain reaction (RT-PCR), RNA was isolated from naïve CD14+ monocytes with RNeasy Mini Kit (Qiagen, Germantown, MD, USA) according to the manufacturer’s instructions. RT-PCR was carried out using GeneAmp RNA PCR Core kit (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer’s instructions. DNase-treated RNA samples were reverse transcribed to complement DNA (cDNA) using recombinant Moloney murine leukaemia virus reverse transcriptase.